Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/08/2003US20030087339 Alzheimer's disease; Parkinson's disease; rheumatic disorders
05/08/2003US20030087319 Novel protein
05/08/2003US20030087317 Human NIM1 kinase
05/08/2003US20030087315 Inhibitors of collagen assembly
05/08/2003US20030087307 Compound for use in the prevention and treatment of respiratory and nervous system disorders
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087305 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/08/2003US20030087304 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/08/2003US20030087299 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/08/2003US20030087295 Methods and compositions for the treatment and diagnosis of pain disorders using 9805
05/08/2003US20030087294 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof
05/08/2003US20030087287 Novel g-protein-coupled receptor protein and dna thereof
05/08/2003US20030087274 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/08/2003US20030087266 IGs as modifiers of the p53 pathway and methods of use
05/08/2003US20030087264 Detection of regulatory response to pulsatile electromagnetic stimulus; obtain tissue sample, insert probe, apply pulsatile stimulus, detect gene expression, classify genes which are expresed
05/08/2003US20030087255 Peptides which stimulate the immune response and tissue regeneration
05/08/2003US20030087249 93870, a human G-protein coupled receptor and uses therefor
05/08/2003US20030087247 Diagnosis and treatment of inflammation and hyperactive immune conditions
05/08/2003US20030087246 Nucleic acids of the human ABCA12 gene, vectors containing such nucleic acids and uses thereof
05/08/2003US20030087243 Diagnosis, prognosis and treatment of cancer related to the Barx2 gene
05/08/2003US20030087241 Circular DNA vectors for synthesis of RNA and DNA
05/08/2003US20030087232 Methods for screening polypeptides
05/08/2003US20030086947 For diagnosis and prevention of ungulate diseases caused by treponeme spirochete bacteria
05/08/2003US20030086943 Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
05/08/2003US20030086942 Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
05/08/2003US20030086941 For diagnosing and therapy of gastrin-dependent tumor
05/08/2003US20030086938 Effecting presentation to the animal's immune system of an immunogenically effective amount of at least one analogue of autologous beta amyloid (A beta ) protein or autologous amyloid precursor
05/08/2003US20030086937 For therapy and prophylaxis of disease
05/08/2003US20030086936 For use in hematopoietic therapy; for arresting proliferation of leukemic cells
05/08/2003US20030086934 Basal cell markers in breast cancer and uses thereof
05/08/2003US20030086931 Therapy of cancers
05/08/2003US20030086930 Administering CTLA-4 (cytotoxic T lymphocyte antigen-4) antibodies for therapy of cancer
05/08/2003US20030086927 Administering to a host an agent which inhibits cyclin G1 protein, agent being administered in amount effective to inhibit cyclin G1 protein in tumor cells of host
05/08/2003US20030086925 Treatment of autoimmune diseases
05/08/2003US20030086923 Method for the prevention and/or treatment of atherosclerosis
05/08/2003US20030086922 Administering a bispecific antibody comprising a first binding site capable of recognizing and binding a first antigen Fc gamma RIII and second binding site capable of recognizing and binding a second antigen
05/08/2003US20030086921 For therapy and prophylaxis of allergic conditions, autoimmune diseases and inflammatory diseases
05/08/2003US20030086920 Administering derivative of angiotensin I for the onset of the renal related disorder to be prevented, inhibited or delayed or the symptoms of the renal-related disorder to be ameliorated
05/08/2003US20030086919 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
05/08/2003US20030086918 For specific cleavage and purification of poly amino acids that have low solubilities
05/08/2003US20030086917 Use of sphingomyelinase for producing dermatological and/or cosmetic compositions suitable to be topically applied, to increase the levels of skin and mucosal ceramides
05/08/2003US20030086912 Antisense modulation of microsomal triglyceride transfer protein expression
05/08/2003US20030086909 Composition and method for improving function of embryonic kidney transplants
05/08/2003US20030086906 Method of inducing an immune response using vaccinia virus recombinants
05/08/2003US20030086904 Therapeutic regimen for treating cancer
05/08/2003US20030086903 Therapeutic regimen for treating cancer
05/08/2003US20030086901 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
05/08/2003US20030086900 Method of treatment using ligand-immunogen conjugates
05/08/2003US20030086893 Morphogenesis; therapy
05/08/2003US20030086879 Immunopotentiators
05/08/2003US20030086877 Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
05/08/2003CA2756610A1 Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
05/08/2003CA2466326A1 Tri-, tetra-, and penta-peptides having antiangiogenic activity
05/08/2003CA2466306A1 Di-, tri,- and tetra-peptides having antiangiogenic activity
05/08/2003CA2466152A1 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003CA2466032A1 Methods and dosage forms for improving the bioavailability of therapeutic agents
05/08/2003CA2465874A1 Thymosin alpha 1 (ta1) peptides conjugates to polyethylene glycol (peg) polymers
05/08/2003CA2465792A1 Non-neurotoxic plasminogen activating factors for treating of stroke
05/08/2003CA2465714A1 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
05/08/2003CA2465639A1 Tumor antigen
05/08/2003CA2465371A1 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465188A1 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor
05/08/2003CA2465183A1 Compositions and methods for the therapy and diagnosis of lung cancer
05/08/2003CA2465123A1 Dermopharmaceutically and cosmetically active oligopeptides
05/08/2003CA2465037A1 Genetic vaccine against human immunodeficiency virus
05/08/2003CA2464995A1 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003CA2464945A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003CA2464887A1 Methods and compositions for treating parkinson's disease
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003CA2464307A1 Method of administering a thymosin alpha 1 peptide
05/08/2003CA2464199A1 A composition and method to alter lean body mass and bone properties in a subject
05/08/2003CA2463977A1 Method of treatment of vulval vestibulitis
05/08/2003CA2463091A1 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
05/08/2003CA2462660A1 Nucleic acid-associated proteins
05/08/2003CA2458850A1 Fibrin nanoparticles and uses thereof
05/08/2003CA2441755A1 Human secreted proteins
05/08/2003CA2407548A1 Psp94: use for treatment of hypercalcemia and bone metastasis
05/08/2003CA2361462A1 Induction of tolerance to a therapeutic polypeptide
05/07/2003EP1308515A2 Porcine factor VIII
05/07/2003EP1308514A2 ICAM-4 Materials and Methods
05/07/2003EP1308513A1 Use of polypeptide
05/07/2003EP1308512A1 Novel proteins and dnas thereof
05/07/2003EP1308511A1 Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature.
05/07/2003EP1308509A1 Novel physiologically active peptide and use thereof
05/07/2003EP1308461A2 Antibodies to beta-amyloids or their derivatives and use thereof
05/07/2003EP1308460A2 Method and apparatus for preparing an acellular red blood cell substitute
05/07/2003EP1308458A1 New polynucleotides and polypeptides of the CX26 gene
05/07/2003EP1308172A1 Method for protein-preserving purification of contaminated biological liquids
05/07/2003EP1308170A2 Dried blood factor composition comprising trehalose
05/07/2003EP1308166A1 Desmodus Salivary Plasminogen Activator (DSPA) for the treatment of strokes
05/07/2003EP1308165A1 Skin wound healing promoters
05/07/2003EP1307588A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
05/07/2003EP1307582A2 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
05/07/2003EP1307568A2 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
05/07/2003EP1307567A2 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme
05/07/2003EP1307564A2 Compounds and methods for treatment and diagnosis of chlamydial infection
05/07/2003EP1307559A2 Slit-like protein obtained from a cdna library from hs-5 stromal cell line
05/07/2003EP1307558A2 Novel ebi-3-alt protein and nucleic acid molecules and uses therefor
05/07/2003EP1307557A2 Endothelial cell expression patterns
1 ... 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 ... 3163